SWM
ATOS icon

Spire Wealth Management’s Atossa Therapeutics ATOS Stock Holding History

Spire Wealth Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,687
Closed -$109K – 2191
2022
Q2 		$109K Buy
6,687
+420
+7% +$6.62K ﹤0.01% 1002
2022
Q1 		$118K Buy
6,267
+2,534
+68% +$51.5K ﹤0.01% 1108
2021
Q4 		$90K Sell
3,733
-334
-8% -$12.2K ﹤0.01% 1442
2021
Q3 		$199K Buy
4,067
+867
+27% +$50.4K 0.01% 927
2021
Q2 		$335K Buy
3,200
+200
+7% +$10.6K 0.01% 732
2021
Q1 		$95K Buy
+3,000
New +$110K ﹤0.01% 1417

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Spire Wealth Management's ATOS Position: Q3 2022 in Review

Spire Wealth Management sold out of Atossa Therapeutics (ATOS) in Q3 2022, closing a stake of 6,687 shares — an estimated $109K sold.

Spire Wealth Management first reported a position in ATOS in Q1 2021 and held it in 6 quarters. The position peaked at $335K in Q2 2021. 56 funds tracked by Wall St. Rank hold ATOS as of Q3 2022.

  • Spire Wealth Management reported no remaining Atossa Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Spire Wealth Management sold 6,687 Atossa Therapeutics shares in Q3 2022, an estimated $109K.
  • Spire Wealth Management first reported a position in Atossa Therapeutics in Q1 2021 and held it in 6 quarters.
  • Spire Wealth Management's Atossa Therapeutics position peaked at $335K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2022.

Based on Spire Wealth Management's 13F filing for Q3 2022, filed 7 Nov 2022.